PCIF1-mediated m6Am RNA methylation modulates disease pathogenesis and progression
When the first nucleotide immediately downstream of the m 7 G cap at the 5′ end of eukaryotic mRNA is 2′-O-methyladenosine (Am), methylation at its N6 position can occur to form N6,2′-O-dimethyladenosine (m 6 Am). m 6 Am RNA modification is dynamically regulated by PCIF1 and FTO. In recent years, numerous studies have demonstrated that PCIF1-mediated m 6 Am modification participates in various biological processes, including the cell cycle, nutrient and energy metabolism, immune regulation and stress responses. Moreover, abnormal m 6 Am levels and dysregulated expression of related enzymes are widely involved in the tumorigenesis, progression and chemoresistance of tumors in the head and neck, digestive system, urinary system and nervous system, representing important factors affecting patient prognosis and treatment. Meanwhile, dysregulation of m 6 Am and its modifying enzymes also plays an important role in pain–anxiety comorbidity and periodontitis.
Authors
- Tongbao Feng (ORCID: https://orcid.org/0000-0002-8596-2916)
- Yingying Li
- Ziteng Wang
Institutions
- Nanjing Traditional Chinese Medicine Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Changzhou No.2 People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3389/fonc.2026.1966707
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jiangsu Commission of Health